Editorial
doi: 10.3390/life15030363.
Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy
Affiliations
- PMID: 40141708
- PMCID: PMC11943963
- DOI: 10.3390/life15030363
Item in Clipboard
Editorial
Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy
Life (Basel).
.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is currently one of the most common hepatic disorders observed in daily medical practice [...].
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.J Clin Exp Hepatol. 2012 Jun;2(2):145-55. doi: 10.1016/S0973-6883(12)60103-0. Epub 2012 Jul 21. J Clin Exp Hepatol. 2012. PMID: 25755423 Free PMC article.
-
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4. Metabolism. 2017. PMID: 28521870 Review.
-
Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.JHEP Rep. 2022 Oct 28;5(2):100615. doi: 10.1016/j.jhepr.2022.100615. eCollection 2023 Feb. JHEP Rep. 2022. PMID: 36687468 Free PMC article.
-
Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.J Gastroenterol Hepatol. 2021 Mar;36(3):629-636. doi: 10.1111/jgh.15172. Epub 2020 Jul 16. J Gastroenterol Hepatol. 2021. PMID: 32627871 Review.
-
Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease.Eur J Radiol. 2018 Oct;107:7-13. doi: 10.1016/j.ejrad.2018.08.008. Epub 2018 Aug 11. Eur J Radiol. 2018. PMID: 30292275
References
-
- Lazarus J.V., Mark H.E., Anstee Q.M., Arab J.P., Batterham R.L., Castera L., Cortez-Pinto H., Crespo J., Cusi K., Dirac M.A., et al. NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: A consensus statement. Nat. Rev. Gastroenterol. Hepatol. 2022;19:60–78. doi: 10.1038/s41575-021-00523-4. - DOI - PubMed
-
- Amini-Salehi E., Letafatkar N., Norouzi N., Joukar F., Habibi A., Javid M., Sattari N., Khorasani M., Farahmand A., Tavakoli S., et al. Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries. Arch. Med. Res. 2024;55:103043. doi: 10.1016/j.arcmed.2024.103043. - DOI - PubMed
-
- Kounatidis D., Vallianou N.G., Geladari E., Panoilia M.P., Daskou A., Stratigou T., Karampela T., Tsilingiris D., Dalamaga M. NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics. Biomedicines. 2024;12:826. doi: 10.3390/biomedicines12040826. - DOI - PMC - PubMed
-
- Xiao J., Han Ng C., Chan K.E., Fu C., Tay P., Yong J.N., Lim W.H., Tan D.J.H., Syn N., Wong Z.Y., et al. Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD—An Umbrella Overview of Systematic Review of Meta-Analysis. J. Clin. Exp. Hepatol. 2023;13:656–665. doi: 10.1016/j.jceh.2022.11.006. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
